2.8K
Downloads
39
Episodes
The Mesothelioma Applied Research Foundation developed MesoTV in response to the need to cancel our annual International Symposium on Malignant Mesothelioma. In our first season we covered a number of topics, many focused on the immediate effects of Covid-19 on mesothelioma treatment. In our second season and beyond, we focus on more traditional topics such as advances in treatment, mesothelioma science, the patient and caregiver experience and quality of life.
Episodes
Monday Feb 27, 2023
Monday Feb 27, 2023
Separately, chemotherapy and immunotherapy are both approved to treat mesothelioma, and individually they work equally well for those patients with the epithelioid type of disease. Currently, the question in front of scientists is what happens when those two treatments are combined? DREAMER, a new clinical trial enrolling right now in the United States and Australia, is looking to find those answers. In this episode of MesoTV we talk with one of the principal investigators of this study, Dr. Patrick Forde of Johns Hopkins, to ask him about what this trial means to patients. If a patients is considering enrolling in this trial, they should watch this episode. The interview is moderated by Shannon Sinclair, RN, BSN, OCN, the oncology nurse at the Mesothelioma Applied Research Foundation. www.curemeso.org.
MesoTV is a program by the Mesothelioma Applied Research Foundation. This program is made possible by our generous sponsors: Maune Raichle Hartley French & Mudd, LLC (MRHFM); Bristol Myers Squibb; Novocure, Merck, The Gori Law Firm, TCR2, AstraZeneca, Early Lucarelli Sweeney & Meisenkothen.
Search our previous episodes for topics/speakers of interest to you at www.curemeso.org/mesotv.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.